You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
GIOTRIF is indicated as monotherapy for the treatment of adult patients with:, Locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. Tumours must have activating Epidermal Growth Factor Receptor (EGFR) mutations., Locally advanced or metastatic squamous non-small cell carcinoma of the lung progressing on or after platinum-based chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
GIOTRIF is indicated as monotherapy for the treatment of adult patients with:, Locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. Tumours must have activating Epidermal Growth Factor Receptor (EGFR) mutations., Locally advanced or metastatic squamous non-small cell carcinoma of the lung progressing on or after platinum-based chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
GIOTRIF is indicated as monotherapy for the treatment of adult patients with:, Locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. Tumours must have activating Epidermal Growth Factor Receptor (EGFR) mutations., Locally advanced or metastatic squamous non-small cell carcinoma of the lung progressing on or after platinum-based chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
GIOTRIF is indicated as monotherapy for the treatment of adult patients with:, Locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. Tumours must have activating Epidermal Growth Factor Receptor (EGFR) mutations., Locally advanced or metastatic squamous non-small cell carcinoma of the lung progressing on or after platinum-based chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
